What's new? Log in Free sign up

Galapagos (GLPG)

Company Profile

Company profile

Ticker

GLPG, GLPGF

Exchange

Website

CEO

Dr. Paulus A. Stoffels M.D., Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

DATARAM CORP

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

GLPG stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Galapagos to Present at Upcoming Investor Conferences

Galapagos receives transparency notification and 13D filing from Tang Capital

Current report (foreign)

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Current report (foreign)

Registration of securities for employees

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Transcripts

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

TANG CAPITAL MANAGEMENT LLC

GILEAD SCIENCES, INC.

EcoR1 Capital, LLC

EcoR1 Capital, LLC

GILEAD SCIENCES, INC.

EcoR1 Capital, LLC

EcoR1 Capital, LLC

EcoR1 Capital, LLC

Financial summary

Financial statements Chart GLPG financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Galapagos earnings reports.

Institutional ownership, Q4 2024

GLPG institutional ownership history Ownership history

54.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	83	24	+245.8%
Opened positions	63	5	+1160.0%
Closed positions	4	67	-94.0%
Increased positions	8	9	-11.1%
Reduced positions	8	4	+100.0%

13F shares	Current	Prev Q	Change
Total value	855.20 bn	5.96 bn	+14239.3%
Total shares	35.70 mm	32.34 mm	+10.4%
Total puts	126.40 k	0.00	NEW
Total calls	209.70 k	0.00	NEW
Total put/call ratio	0.6	–	–

Largest owners	Shares	Value	Change
GILD Gilead Sciences	16.71 mm	$461.73 bn	-20.4%
Van Herk Investments B.V.	4.64 mm	$0.00	0.0%
Tang Capital Management	2.16 mm	$59.43 bn	NEW
FMR	1.59 mm	$43.86 bn	NEW
BVF	1.57 mm	$43.16 bn	NEW
Deerfield Management	1.41 mm	$38.80 bn	NEW
Prosight Management	1.02 mm	$28.19 bn	NEW
Deep Track Capital	780.78 k	$21.47 bn	NEW
Segall Bryant & Hamill	685.87 k	$18.86 bn	NEW
Finepoint Capital	674.76 k	$18.56 bn	NEW

Largest transactions	Shares	Bought/sold	Change
EcoR1 Capital	155.01 k	-6.35 mm	-97.6%
GILD Gilead Sciences	16.71 mm	-4.27 mm	-20.4%
Tang Capital Management	2.16 mm	+2.16 mm	NEW
FMR	1.59 mm	+1.59 mm	NEW
BVF	1.57 mm	+1.57 mm	NEW
Deerfield Management	1.41 mm	+1.41 mm	NEW
Prosight Management	1.02 mm	+1.02 mm	NEW
Deep Track Capital	780.78 k	+780.78 k	NEW
Segall Bryant & Hamill	685.87 k	+685.87 k	NEW
Finepoint Capital	674.76 k	+674.76 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Galapagos Receives Transparency Notification And 13D Filing From Tang Capital That It Holds 7.5% Of Total Outstanding Shares Of The Company

Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on February 14, 2025 on behalf of Mr. Kevin Tang, Tang Capital Management, LLC ("TCM"), Tang Capital Partners, LP ("TCP"),

Morgan Stanley Downgrades Galapagos to Underweight, Lowers Price Target to $22

Morgan Stanley analyst Judah Frommer downgrades Galapagos (NASDAQ:GLPG) from Equal-Weight to Underweight and lowers the price target from $31 to $22.

Galapagos Q4 EPS $0.30, Sales $80.58M (Converted To USD)

Galapagos (NASDAQ:GLPG) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $(0.35) by 185.71 percent. This is a 88.64 percent decrease over earnings of $2.64 per share from the

Earnings Scheduled For February 12, 2025

Barclays Downgrades Galapagos to Underweight

Press releases

From Benzinga Pro

Galapagos to Present at Upcoming Investor Conferences

Mechelen, Belgium; February 24, 2025, 22:01 CET – Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today

Galapagos receives transparency notification and 13D filing from Tang Capital

Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification and 13D filing from Tang Capital. Pursuant to Belgian

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.